



303 Rec'd PCT/PTO 18 DEC 1998
PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY. DOCKET: WALLACH=21

In re Application of:)	Art Unit:
)	
WALLACH et al.)	Examiner:
)	
Appln. No.: 09/155,676)	Washington, D.C.
)	
Filed: April 1, 1997)	December 18, 1998
)	
For: MODULATOR OF TNF)	
RECEPTOR ASSOCIATED FACTOR...)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR 1.97, as it is filed before the mailing date of a first office action on the merits.

[X] 2. In accordance with 37 CFR 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached.

[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).


[] 4. Other information being provided for the examiner's consideration follows:

5. In accordance with 37 CFR 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and applicant reserves the right to prove that the date of publication is in fact different.


Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By:


Sheridan Neimark
Reg. No. 20,520

419 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
SN:lt



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

WALLACH=21

SERIAL NO.

09/155,676

LIST OF DOCUMENTS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT: David WALLACH et al.

FILING DATE: April 1, 1997

GROUP:

FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	AA	9	7	0	6	1	8	2	20FE1997	PCT			XXX	
	AB													
	AC													
	AD													
	AE													

OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)

AF	Mosialos et al., "The Epstein-Barr Virus Transforming Protein LMP1 Engaging Signaling Proteins for the Tumor Necrosis Factors Receptor Family", <u>Cell</u> , 80:389-399, (1995)
AG	Cheng et al., "TANK, a co-inducer with TRAF2 of TNF- and CD40L-mediated NF-KB activation", (1995)
AH	Vandenabeele et al., "Two tumour necrosis factors receptor: structure and function", <u>Trends in Cell Biology</u> , 5:392-399, (1995)
AI	Malinin et al., "MAP3K-related kinase involved in NF-kB induction by TNF, CD95 and IL-1", <u>Nature</u> , 385:540-544 (1997)
AJ	Rothe et al., "The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins", <u>Cell</u> , 83:1243-1252, (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.